The Plasma Shot (Passive Vaccine)
Now that we are thankfully seeing a lower level of infection in the tri-state area and many other areas across the USA, the vulnerable among us are wondering when they can resume normal life. Grandparents long to kiss their grandchildren and children of the immunocompromised yearn to play with their peers. How can we protect the at-risk as we return to normal?
Hyperimmune globulin (HiG) may be the solution to this problem. HiG consists of concentrated antibodies from convalescent COVID-19 plasma which may protect vulnerable individuals from infection. Concentrated antibodies have been used to treat many diseases over the past century, such as diphtheria, polio, measles, and rabies .
Vaccines for a specific disease elicit immunity in individuals by stimulating their immune system to provoke a response to that disease . A COVID-19 vaccine may not be available for many months . Concentrated COVID-19 antibodies (HiG) may serve as a substitute by providing passive immunity so that individuals need not be concerned about infection for 1-4 months after injection .
HiG Intramuscular Injection
HiG can theoretically be administered as an intravenous infusion (into the vein) or as an intramuscular injection (into the muscle). While the CoVIg-19 Plasma Alliance is developing an intravenous HiG product , we are focusing on intramuscular HiG injections. We believe that intramuscular HiG has superior applications., since intramuscular injections require less training to administer and can easily be implemented outside the hospital/clinic setting (e.g. in nursing homes, etc.).
We are working with researchers at Columbia University, Case Western University, Johns Hopkins University, and multiple hospitals to perform clinical trials on the efficacy of the HiG shot. We have discussed the possible manufacturing of HiG injections with ADMA Biologics, Inc., a well-regarded, public company with years of experience in manufacturing HiG products .
Clinical trials are focused on the following three areas:
Pure Prophylaxis: injections are administered in any high-risk population (e.g. elderly, nursing homes, front-line workers) to provide passive immunity for 1-4 months.
Post-exposure Prophylaxis: injections are administered to those who have been exposed to COVID-19 to prevent active COVID-19 infection
Mild Treatment: injections are administered to treat those who have become ill with mild COVID-19
Additionally, HiG has been used to treat severe infection in a young COVID-19 patient in Israel with highly promising results .
Since nursing home residents are at high-risk for severe COVID-19 (some estimate that a third of COVID-19 deaths in the US are of nursing home residents or staff) , nursing homes are eager to prevent illnesses among their residents. We have several nursing home industry chains who will participate in clinical trials to test the success of the HiG shot in preventing infection in their residents.
Using HiG Injections as a Passive Vaccine
Since HiG products require convalescent COVID-19 plasma, their supply is limited by the amount of plasma donated. HiG shots will be prioritized for high-risk individuals. Additionally, HiG products may potentially be given to close contacts of infected individuals to prevent further outbreaks. This approach is similar to the ring vaccination strategy of vaccinating close contacts of infected patients, which has been successfully used to eradicate smallpox .
Community Voucher Program
Plasma donors would like to be assured that their relatives are able to receive convalescent plasma if they become ill and that their high-risk relatives are able to receive the HiG shot.
Economists Scott Kominers, Parag Pathak, Tayfun Sönmez, and Utku Ünver have produced an incentive scheme that would allow plasma donors to receive community credits for each plasma donation . The community credits can be used by family members or friends of the donor for priority access to HiG products. By donating plasma, you may receive a passive vaccine credit to allow your parent and/or grandparent to live normally.
Additionally, potential plasma recipients (e.g. ill patients) can pledge to donate plasma when they recover, and thereby receive priority access for HiG.